- Home
- MKTW vs IGC Comparison
MKTW vs IGC Comparison
Compare MKTW & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | IGC |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 33.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MKTW | IGC |
|---|---|---|
| Price | $16.05 | $0.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $20.00 | $4.13 |
| AVG Volume (30 Days) | 8.0K | ★ 652.8K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $342,206,000.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | $6.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.08 | $0.25 |
| 52 Week High | $21.74 | $0.50 |
Technical Indicators
Market Signals| Indicator | MKTW | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 50.19 |
| Support Level | $15.90 | $0.32 |
| Resistance Level | $16.65 | $0.36 |
| Average True Range (ATR) | 0.37 | 0.03 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 9.24 | 69.65 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.